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Lung cancer is one of the most prevalent cancers in both men and women worldwide. The
nucleic acid G4 structures have been implicated in the transcriptional programmes of
cancer-related genes in some cancers such as lung cancer. However, the role of the
dominant G4 resolvase DHX36 in the progression of lung cancer remains unknown. In this
study, by bioinformatic analysis of public datasets (TCGA and GEO), we find DHX36 is an
independent prognosis indicator in non-small-cell lung carcinoma (NSCLC) with subtype
dependence. The stable lentiviral knockdown of the DHX36 results in accelerated
migration and aggregation of the S-phase subpopulation in lung cancer cells. The
reduction of DHX36 level de-sensitises the proliferation response of lung cancer cells to
chemotherapeutic drugs such as paclitaxel with cell dependence. The knockdown of this
helicase leads to promoted tumour growth, demonstrated by a 3D fluorescence spheroid
lung cancer model, and the stimulation of cell colony formation as shown by single-cell
cultivation. High throughput proteomic array indicates that DHX36 functions in lung
cancer cells through regulating multiple signalling pathways including activation of
protein activity, protein autophosphorylation, Fc-receptor signalling pathway, response
to peptide hormone and stress-activated protein kinase signalling cascade. A causal
transcriptomic analysis suggests that DHX36 is significantly associated with mRNA
surveillance, RNA degradation, DNA replication and Myc targets. Therefore, we unveil
that DHX36 presents clinical significance and plays a role in tumour suppression in lung
cancer, and propose a potentially new concept for an anti-cancer therapy based on
helicase-specific targeting.
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Lung cancer remains the most common cancer in both men and
women worldwide, and the most common cause of cancer-
related death (1). Despite the advances in research and patient
care, only around 16% of lung cancer cases are diagnosed at an
early stage and, for those patients with metastasis, the five-year
survival rate is just 5% (2). Within all the unmet needs, the
identification of new biomarkers for diagnosis, prognosis and
treatment should still be addressed for the better care of lung
cancer patients (3).
Guanine-quadruplex secondary structures (G4) are an
architecture of nucleic acids that occur in guanine-rich
sequences. They are four-stranded helical structures mediated by
Hoogsteen hydrogen bonds formed between four guanines in a
single plane, stabilised by a monovalent cation. G4s are alternative
nucleic acid structures involved in essential nucleic acid metabolic
processes including transcription, translation, RNA stability, DNA
replication, DNA repair, and telomere maintenance (4–6). G4
structures function in gene transcription and post-transcriptional
regulation of both coding and non-coding RNAs (7). G4s are
enriched in gene promoter regions, regulatory regions of the
human genome and untranslated regions of mRNAs (8–10). G4
motifs are present in the promoter regions of some proliferation-
associated genes, proto-oncogenes, telomeres, repetitive DNA
regions, and also in immunoglobulin heavy chain genes (11, 12).
G4 structures at the promoters act as transcription repressors (13).
Therefore, removing the G4 structure by replacing the critical
guanine residues with adenines produces a several-fold increase in
the transcription levels (14). G4 motifs in promoter regions may
play a role in the regulation of genes involved in cell cycle
regulation (13). G4 motifs in untranslated regions of some
mRNAs can diminish their translation efficiency (15). G4s are
found in the promoters of a wide range of cancer-related genes
such as proto-oncogeneMYC (14, 16), B cell lymphoma 2 (BCL-2)
(17, 18), vascular endothelial growth factor (VEGF) (19), hypoxia-
inducible factor 1a (HIF1a) (20), the transcription factor MYB
(21), platelet-derived growth factor a polypeptide (PDGFA) (22),
PDGF receptor b polypeptide (PDGFRb) (23), KRAS (24–26),
retinoblastoma protein 1 (RB1) (27, 28), mixed-lineage leukaemia
(MLL) proto-oncogene (29) and human telomerase reverse
transcriptase (TERT) (30). These genes are known to be
implicated in cancer and are associated with the six hallmarks of
cancer (31, 32).
The DEAH-box polypeptide 36 (DHX36) is also known as
RNA helicase associated with the AU-rich RNA element (RHAU)
or G4 resolvase-1 (G4R1). It is an ATP-dependent RNA helicase
highly specific for DNA and RNA G4s (33, 34). The DEAH
represents the code of the amino acids constituting motif II of the
helicase domain (Asp-Glu-Ala-His) (35, 36). RNA helicases
constitute a large group of essential enzymes that unwind or
rearrange duplex and structured RNAmolecules and function in a
wide range of major RNA processing events (37–40). They are
crucial to maintain genomic integrity and initiate the proper
transcription and translation, by unwinding of nucleic acid
secondary structures within cells. DHX36 can specifically bind
and unwind the G4 motifs with its ATPase and resolving activity.Frontiers in Oncology | www.frontiersin.org 2DHX36 is considered as the major source of G4-DNA- and G4-
RNA-resolving activities (41, 42). For example, DHX36 is found to
play a critical role in the remodelling of G4s within the 5’-end of
the human telomerase RNA. DHX36 resolution of telomeric RNA
or DNA G4s activates telomerase for telomere elongation and
increases RNA accumulation (43–45).
Structurally, DHX36 contains a conserved RNA helicase core
region of approximately 440 amino acids, which consists of at
least six discrete functional domains (46). The primary amino
acid sequences of DHX36 consist of a region of the first 105
amino acids, which is termed as the RHAU-specific motif (RSM)
and is essential and sufficient for direct RNA interactions, as well
as its localization to stress granules in HeLa cells (47). A highly
conserved 18 amino acid core sequence within this region is
necessary for interaction with both RNA and DNA G4s (48).
DHX36 has been initially found to be a critical factor in
immunity. DHX36 functions as a DNA or double-stranded
RNA (dsRNA) sensor in dendritic cells (49–51). It is a key
molecule in RIG-I signalling that acts by forming an antiviral
stress granule with dsRNA-dependent protein kinase (PKR), in a
dsRNA-dependent manner, to execute antiviral reactions (47, 51,
52). Further, DHX36 plays a critical role in the interferon (IFN)
signalling pathway by forming the DDX1-DDX21-DHX36
complex for dsRNA sensing (50).
The clinical significance and role of DHX36 in cancer are
poorly understood, regardless of enormous indirect clues and a
few highly specific studies. For example, DHX36 downregulates
paired like homeodomain 1 (PITX1) while it upregulates Yin
Yang 1 (YY1) transcription factor (53). These two genes both
have G4 structures in their promotor regions and play diverse
roles in modulating cancer progression. In response to UV-
Induced DNA damage, DHX36 regulates the tumour suppressor
p53 pre-mRNA 3’-end processing (54). Also, an RNA gene
named G-Quadruplex Forming Sequence Containing LncRNA
(GSEC) can bind to DHX36 via its G4 sequence, leading to the
antagonisation of DHX36 and enhanced migration of colon
cancer cells (55). In this study, we intended to evaluate the
differential expression and prognostic value of DHX36 in
patients with non-small-cell lung carcinoma (NSCLC). The
role of DHX36 in lung cancer cells was also investigated using
stable lung cancer cell models following DHX36 knockdown.METHODS
Clinical Significance Analysis
Overall survival analysis of DHX36 in lung cancer was conducted
using the Kaplan-Meier plotter (https://kmplot.com). The probes
of DHX36 were 223138_s_at, 223139_s_at and 223140_s_at.
Patients were split by Auto select best cut-off. The size of
eligible patients was 1144. Subtype breakdown meta-analysis of
the survival analysis from different studies was performed using
the web server of Lung Cancer Explorer (http://lce.biohpc.
swmed.edu), which integrated the following eligible genomic
data of GSE72094 (n=442) (56), TCGA (LUAD, n=576; LUSC,
n=552) (https://www.cancer.gov/tcga), GSE30219 (n=307) (57),
GSE41271 (n=275) (58), GSE31210 (n=224) (59), GSE31210April 2021 | Volume 11 | Article 655757
Cui et al. DHX36 in Lung Cancer(224) (60), GSE37745 (n=196) (61), GSE50081 (n=181) (62),
GSE42127 (n=176) (63), GSE11969 (n=163) (64), GSE19188
(n=156) (65), GSE13213 (n=117) (66), GSE3141(n=111) (67),
GSE74777 (107) (68), GSE26939 (n=101) (69), GSE1037 (n=80)
(70), GSE29016 (n=72) (71), GSE12472 (n=63) (72), GSE31548
(n=50) (73), GSE10245 (n=48) (74), GSE11117 (n=44) (75).
Validation of DHX36 Expression in Human
Lung Cancer Cohort From an In-House
Lung Cancer Cohort
To verify the gene expression level of DHX36, in addition to the
findings from the public available datasets, we carried out
analyses of DHX36 expression on an existing lung cancer
cohort of lung cancer patients with long-term follow-up from
Peking University Cancer Hospital. Lung cancer and adjacent
normal tissues were collected immediately after surgery and
stored in liquid nitrogen until use. The study was approved by
local ethics committees (Peking University Cancer Hospital) and
performed in accordance with guidelines established by the
World Medical Association Declaration of Helsinki. Written
consent was obtained from all patients.
Cell Lines and Culture Conditions
The lung cancer cell lines were purchased from the American
Type Culture Collection (ATCC) and maintained at a low
passage (less than 20). Cells were cultured at 37°C in a
humidified incubator supplied with 5% CO2. Cells were grown
in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich,
Dorset, UK). Growth media for each cell line was supplemented
with 10% foetal calf serum (FCS, PAA Laboratories Ltd.,
Somerset, UK), penicillin (100 U/ml), and streptomycin (100
mg/ml) (Sigma–Aldrich).
The A549 cell line is originally derived through explant
cultivation of lung carcinomatous tissue from a 58-year-old
Caucasian male, while SK-MES-1 is derived from the pleural
effusion of a 65-year-old Caucasian male with lung squamous
cell carcinoma. Both cell lines are hypotriploid in terms of their
stemline chromosome number and possess relatively high
frequencies of chromosome abnormality including number and
structures. More details of the Karyotypes of these two cell lines
can be found from ATCC (https://www.lgcstandards-atcc.org).
Lentiviral Infection With DHX36 shRNA
Lentiviral vectors containing short hairpin RNAs (shRNA)
specific for DHX36 and the control shRNA (Scr shRNA) were
obtained from VectorBuilder (Santa Clara, CA, USA). The
vectors were assembled with EGFP as a reporter and
neomycin-resistant gene for selection. HEK293T packaging
cells were transduced with viral packaging (psPAX2), viral
envelope (pMD2G) and lentiviral plasmid vectors using serum-
free OPTI-MEM (Invitrogen, Carlsbad, CA, USA) and FuGENE
6 transfection reagent (Promega, Southampton, UK). Four and
five days after transfection, the supernatant containing the
packaged viral particles was collected and filtered through a
0.45 µm filter. The cancer cells were then infected using the
lentiviral supernatant in the presence of 8 mg/ml PolybreneFrontiers in Oncology | www.frontiersin.org 3(Sigma-Aldrich). After 48 hours, the cells were subjected to
stable selection with 1.2 mg/ml G418 for 7 days, and
maintained in a growth medium with 300 µg/ml G418. After
selection, the stable lung cancer cell lines steadily expressed GFP,
which could be visualised under a fluorescence microscope.
Cell Proliferation Assay
Lung cancer cells at a density of 2,500 cells/well were seeded onto
96-well tissue culture plates. At designated time points, the cells
were stained with Alamar Blue (Bio-Rad, Cambridge, MA, USA)
following the manufacturer’s instruction. The fluorescence was
read with an excitation wavelength of 530 nm and the emission




The migration ability of the lung cancer cell lines was monitored
using an ECIS system. Briefly, the lung cancer cells at a density of
2.5x104 cell/well were seeded onto ECIS 96W1E array plates
(Applied Biophysics Inc. NY, USA) and the electrical resistance,
due to the interaction of cells and embedded gold-coated
electrodes, was recorded. Once a confluent monolayer was
formed, the cells were subjected to an electric wound at 2800
µA, 60 kHz for 20 s and the rate of change in impedance, as cells
migrated onto the electrode sensing area, was subsequently
monitored and analysed.
Western Blotting
Cultured cells were washed twice in PBS and lysed in a RIPA
buffer containing 50 mM Tris-HCl, 2% SDS, 5% glycerol, 5 mM
EDTA, 1 mM NaF, 10 mM b-glycero-phosphate, 1 mM PMSF, 1
mM Na3VO4 and EDTA-free Protease Inhibitor Cocktail
(Roche, Mannheim, Germany). Protein concentration was
determined by the Pierce BCA protein assay (Thermo
Scientific, Colchester, UK). After normalisation, proteins were
separated by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred with a semi-dry
fast transfer apparatus onto a PVDF membrane (Merck
Millipore Inc., Billerica, USA). The membranes were blocked
with 5% non-fat dried milk (Marvel, Premier Beverages, Stafford,
UK) in PBST solution (0.05% Tween-20 in PBS) for 1 hour at
room temperature. The membranes were then incubated with
the primary antibodies diluted in 5% milk and left overnight
at 4°C. The following day, they were washed in PBST and
incubated with a diluted specific HRP-conjugated secondary
antibody for 1 hour at room temperature. The primary
antibody was DHX36 (diluted 1:1000. GTX131179, GeneTex,
San Antonio, TX, USA) and b-actin (diluted 1:5000. sc 53142,
Santa Cruz). The HRP-secondary antibodies (A5278, Anti-
Mouse IgG; A0545, Anti-Rabbit IgG) were diluted at 1:2000
(Sigma-Aldrich, Dorset, UK). Protein detection was performed
using an EZ-ECL chemiluminescence kit (Biological Industries
USA, Inc., Cromwell, CT, USA). Immunoreactive bands were
visualized and quantified by densitometry using the Syngene
G: BOX chemiluminescence imaging system and Gene Tools
4.03 (Syngene Europe, Cambridge, UK).April 2021 | Volume 11 | Article 655757
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Real-Time PCR Analysis
RNAwas extracted fromcultured cells at 60-80%confluency inT25
flasks or from fresh-frozen tissues using TRI Reagent (Sigma-
Aldrich, Dorset, UK). Total RNA (500 ng) was reverse-
transcribed to complementary DNA (cDNA) using Goscript
Reverse Transcription mix (Promega). Following dilution of
cDNA (1:8), quantitative real-time PCR was performed based on
Amplifluor™ technology, in which a 6-carboxy-fluorescine-tagged
Uniprimer™ (Biosearch Technologies, Inc., Petaluma, CA, USA.)
was used as a probe, along with a pair of specific primers with an
addition of a Z-sequence (actgaacctgaccgtaca) to the 5’-end of the
reverse primer. The primer sequences for qPCR were: DHX36
forward primer, GTTTAAATCAGTTAACCAGACAC; DHX36
reverse primer, ACTGAACCTGACCGTACACGCAATGTT
GGTAGCAATTA; b-actin forward primer, CATTAAGGAGAA
GCTGTGCT; b-actin reverse primer, ACTGAACCTGACC
GTACA GCTCGTAGCTCTTCTCCAG. The qPCR assays were
run in a StepOnePlus system (Thermo Fisher Scientific, Waltham,
MA, USA) and normalised by the corresponding threshold cycle
(CT) values of b-actin mRNA.Flow Cytometry
Cultured cells were detached with trypsin/EDTA and fixed with
the IC fixation buffer (ThermoFisher Scientific) for 1 hour at
room temperature, then resuspended in ice-cold 100%methanol,
and incubated overnight at -20°C. Cells were then washed twice
in FACS buffer (2 mM EDTA in PBS, pH 7.4) and blocked with
1% bovine serum albumin (BSA) in PBS with 0.1% Tween for
1 hour. For the staining with antibodies, cells were incubated
with diluted primary antibodies (1:100) including normal mouse
IgG (14-4714-82, ThermoFisher Scientific) and cleaved poly
(ADP-ribose) polymerase (PARP) (14-6668-82, ThermoFisher
Scientific), respectively, for 1 hour at room temperature. Cells
were then incubated with Alexa Fluor 647-conjugated goat anti-
mouse IgG antibodies (1:1000; A21235, ThermoFisher Scientific)
for 30 minutes at room temperature. For cell cycle analysis, cells
were harvested and blocked as described above, and then directly
incubated with Hoechst 33342 (10 µg/ml. H3570, ThermoFisher
Scientific) for 1 hour at 37°C in the dark. Following the final wash
with FACS buffer, FACS was performed using BD FACS Canto II
flow cytometer equipped with FACS Diva Software (version
6.1.2. BD Biosciences, San Jose, CA, USA). FACS data were
analysed using FCS Express software (version 4. De Novo
Software, Los Angeles, CA, USA).Kaplan–Meier Survival Analysis
The association between DHX36 gene expression and the
survival of the lung cancer patients was assessed using the
pooled gene expression data from www.kmplot.com (Cut-off
value: 1257.33. All probes included). The online tool allowed us
to analyse both the OS (overall survival) and RFS (relapse-free
survival) from 626 cases of lung cancer and the RFS from 1764
cases, which were subjected to expression profiling usingFrontiers in Oncology | www.frontiersin.org 4Affymetrix GeneChip microarray (DHX36 Probeset ID:
223138_s_at; 223139_s_at; 223140_s_at).
Kinexus Kinex Antibody Microarray
Cells were seeded in T75 flasks and incubated in DMEM
supplemented with 10% FCS at 37°C. When the confluence was
approximately 80%, the cells were washed twice and culture
medium was replaced with DMEM containing 2% FCS. After
incubation overnight, cells were suspended in lysis buffer, pH 7.4,
containing 100mM Tris Buffer, 10% 2-ME, 1% NP-40, protease
inhibitor cocktail tablet and 50mMNaF. The lysates were vortexed
and homogenised on a blood wheel for 1 hour at 4°C. The
supernatant of the lysates was then collected by centrifugation for
30 minutes at 15,000 rpm at 4°C The protein concentration in the
supernatant was determined by a fluorescamine protein
quantification assay (Sigma-Aldrich). Proteomic analysis of pan-
specific and phosphorylated proteins was carried out using high
throughput Kinex antibody microarrays (900 antibodies, Kinexus
Bioinformatics) (http://www.kinexus.ca/services).
In Vitro 3D Tumour Spheroid Model
Monolayer cells, under exponential growth conditions, were
resuspended at a density of 5000 cells/ml with 2% Matrigel
(BD Biosciences, Oxford, UK). Cells were then seeded onto a 96-
well Clear Polystyrene Cell-Repellent Microplate (#650970.
Greiner bio-one, Germany) at a density of 500 cells/100 µl/
well. Following overlay with 100 µl of the fresh normal medium,
cells were cultured for 7 days to allow spheroid formation. The
spheroids were then stained with propidium iodide (PI) at a
working concentration of 1 µg/ml for 1 hour. The spheroid
images were captured using the EVOS FL Auto 2 Imaging System
(AMAFD2000. Fisher Scientific, Hemel Hempstead, UK).
Bioinformatic Analysis
The code scripts for bioinformatic analysis were written in R version
3.4.4 (https://www.r-project.org) and Python version 3.9.0 (https://
www.python.org). The IntegratedDevelopment Environment (IDE)
for R was RStudio version 1.3.1093 (RStudio Inc), and the IDE for
Python was the Jupyter Notebook version 6.1.5 (https://jupyter.org).
The Bioconductor packages used in this study were Pathview (76),
clusterProfiler (77) and org.Hs.eg.db version 3.2. 3 (78).
Statistical Analysis
For quantitative measurement, including cell-based assays and
gene expression profiling, the Shapiro-Wilk test was used to
verify whether the data were normally distributed. Unpaired t-
test was used for data with normal distributions whereas, for
non-normal distributions, the Mann-Whitney Rank Test was
applied. When more than two sets of data were compared, either
One-Way ANOVA or the non-parametric Kruskal-Wallis test
was used. Graphs and the statistical analysis were performed
using GraphPad Prism version 8.4.3 (GraphPad Software, San
Diego, CA, USA) or R (version 4.0.3, https://www.r-project.org).
Statistical significance was indicated with the following
nomenclature: *p<0.05, **p<0.01, ***p<0.001.April 2021 | Volume 11 | Article 655757
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Clinical Significance of DHX36 in NSCLC
KM plotting analysis indicated high DHX36 gene expression was
associated with poor overall survival of lung cancer patients
(HR=1.32, logrank p=0.0025, n=1144; Figure 1A). We further
conducted the breakdown meta-analysis of DHX36 gene
expression using all the publicly available transcriptome
studies. As shown in Figure 1B, in LUAD, the HR for random
effect models was 1.20, indicating that the high level of DHX36
gene expression was associated with poor overall survival
(p<0.01). In LUSC (Figure 1C), the HR for random effect
models was 0.98, and the gene expression of DHX36 was not
significantly associated with patient survival (p=0.69), suggesting
there was subtype-dependence.
In all NSCLC samples, gene expression of DHX36 was higher
in the tumour group (n=1017) than in normal tissues (n=110)
(p<0.0001; Figure 1D). In the LUAD subtype, there was a
significant difference in the DHX36 gene expression level
between tumour (n=515) and normal tissue (n=59) groups
(Figure 1E). In the LUSC subset, gene expression of DHX36
was higher in the tumour group (n=502) than in normal tissues
(n=51) (p<0.0001; Figure 1F), which was similar to the pattern
before subtype classification. We also compared the gene
expression of DHX36 among different Tumour-Node-
Metastasis (TNM) staging types. The different T stages were
significant (p=0.01), however, it was not possible to outline the
definitive trends given the wide variation (Figure 1G). There was
no significance observed among the different N (Figure 1H) and
M stages (Figure 1I). It might be important to note that the
limited sample size at certain stages might make the statistical
analysis lack power.
We verified the differential gene expression of DHX36 in
lung cancer using our in-house cohort by qRT-PCR. It showed
that there was a lower expression of the DXH36 gene in the
tumour tissue (p<0.05) despite wide variation (Supplementary
Table 1).Establishment of Stable Lung Cancer Cell
Lines With DHX36 Knockdown (KD)
Given the discrepant association of DHX36 with prognosis and
clinicopathological features, we next attempted to determine the
role of DHX36 in NSCLC. We established stable DHX36-KD cell
lines using two lung cancer cells, A549 and SK-MES-1. As shown
in Figures 2A, B, the qRT-PCR data showed that the gene
expression level of DHX36 was dramatically decreased by
DHX36-shRNA2 but not DHX36-shRNA1 compared to the
SCR control. The FACS data indicated that in A549 cells the
protein level of DHX36 decreased by 24% in the shRNA1 group,
but this level was reduced by 72% in the shRNA2 one (Figures
2C–E). Similarly, in SK-MES-1 cells, the protein level of DHX36
decreased by 42% in the shRNA1 group, while this level was
reduced by 93% by shRNA2 (Figures 2F–H). We then used the
cell lines containing shRNA to validate the change of protein
level usingWestern blot. As shown in Figures 2I, J, the reductionFrontiers in Oncology | www.frontiersin.org 5of DHX36 by shRNA2 was further confirmed in both parental
cell lines. We, therefore, established the stable cell lines using the
shRNA2 and labelled them KD.Knockdown of DHX36 in Lung Cancer
Cells Enhanced Migration
We monitored the real-time migration of stable cell lines using
the ECIS system. In both A549 and SK-MES-1 cells, the
knockdown of DHX36 significantly promoted cell migration
(p<0.05 vs SCR, respectively; Figures 3A, B). We also
determined the cell cycle phase distribution by FACS. As
shown in Figures 3C, D , in A549 cells the S-phase
populations increased from 33.67% in the SCR control to
51.86% in the DHX36-shRNA. Similarly, in SK-MES-1 cells
the S-phase populations increased from 38.62% in the SCR
control to 45.10% in the DHX36 KD group (Figures 3E, F). The
increase of the S-phase indicated the promotion of cell division.
We then investigated the apoptosis of cells in response to the
cytotoxic drug cisplatin. In the four stable cell lines, we
observed an increase in cisplatin-induced apoptosis. However,
there was no significant difference in the cisplatin-induced
increase among the different cell lines, suggesting DHX36
may not be involved in apoptosis induced by cisplatin
(Figures 3G–J).Knockdown of DHX36 Promoted Tumour
Growth in a 3D Culture Environment
We fabricated 3D lung cell spheroids to understand the tumour
growth and change of viability mediated by the knockdown of
DHX36 (Figure 4A). As shown in Figure 4B, the knockdown of
DHX36 increased the integrated median density of GFP, which is
used to quantify the overall cell number compared to the SCR
control in A549 cells (p=0.041). There was also a trend of
decreased PI intensity, which discriminates dead cells (p>0.05).
The ratio of GFP/PI indicated that the DHX36 knockdown
increased the viability of A549 cells dramatically (p=0.00021;
Figure 4C). Likewise, the knockdown of DHX36 in SK-MES-1
cells increased the GFP intensity (p=0.0022), decreased PI
intensity (p=0.0022) and in turn increased the GFP/PI
(p<0.0001) in the spheroids (Figures 4D, E). The data,
therefore, indicated that the knockdown of DHX36 enhanced
the viability of lung cancer cells in 3D spheroid culture. We then
compared the size of spheroids by measuring the area of the
maximum cross sections of individual spheroids. This showed
that the knockdown of DHX36 led to an increase in spheroid size
in both A549 and SK-MES-1 cells (p<0.01 vs SCR, respectively;
Figure 4F).Knockdown of DHX36 Promoted the
Colony Formation of Single-Cell Culture
To understand how single cells proliferate, we performed single-
cell culture in 96 well plates. After single-cell culture for 3 weeks,
there was a significant increase in colony numbers in the DHX36April 2021 | Volume 11 | Article 655757
Cui et al. DHX36 in Lung CancershRNA knockdown groups in both A549 (Figures 5A, B) and
SK-MES-1 cells (Figures 5C, D). The increase in colony
numbers was approximately 2.2 fold in the A549 cells and 1.7
fold in SK-MES-1 cells (Figure 5E). We quantified the relativeFrontiers in Oncology | www.frontiersin.org 6cell number of each colony using the Alamar Blue assay, and
found no difference among the groups, suggesting there was no






FIGURE 1 | Clinical significance of DHX36 in lung cancer. (A)Overall survival analysis of DHX36 in lung cancer using the Kaplan-Meier plotter (https://kmplot.com). The
probes of DHX36 were 223138_s_at, 223139_s_at and 223140_s_at. The patients were split by Auto select best cut-off. The number of eligible patients was n=1144. The
breakdown meta-analysis of survival analysis in LUAD (B) and LUSC (C)was performed using the Lung Cancer Explorer (http://lce.biohpc.swmed.edu), which integrated
the following eligible genomic data of GSE72094 (n=442), TCGA (LUAD, n=576; LUSC, n=552), GSE30219 (n=307), GSE41271 (n=275), GSE31210 (n=224), GSE31210
(224), GSE37745 (n=196), GSE50081 (n=181), GSE42127 (n=176), GSE11969 (n=163), GSE19188 (n=156), GSE13213 (n=117), GSE3141 (n=111), GSE74777 (107),
GSE26939 (n=101), GSE1037 (n=80), GSE29016 (n=72), GSE12472 (n=63), GSE31548 (n=50), GSE10245 (n=48) and GSE11117 (44). (D) Differential expression of
DHX36 gene between tumour and normal tissues in NSCLC. (E) Differential expression of DHX36 gene between tumour and normal tissues in LUAD. (F) Differential
expression of DHX36 gene between tumour and normal tissues in LUSC. (G) Differential expression of DHX36 gene among T staging types in NSCLC. (H) Differential
expression of DHX36 gene among N staging types in NSCLC. (I) Differential expression of DHX36 gene among M staging types in NSCLC.April 2021 | Volume 11 | Article 655757
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Sensitivity to Cytotoxic Drugs
We then evaluated the response of the lung cancer cells to
chemotherapeutic drugs including cisplatin, epirubicin, paclitaxel
and etoposide. Overall, in all the stable cell lines derived from SK-
MES-1 and A549 cells, the four selected drugs reduced cell
proliferation levels dramatically in the cells with both DHX36
knockdown and SCR control. In the stable SK-MES-1 cells (Figure
5G), DHX36 knockdown showed a higher remaining proliferation
level compared to the SCR control in cells treated with cisplatin at
concentrations of 10µM and 20µM (both p<0.01). There was noFrontiers in Oncology | www.frontiersin.org 7response to 50nM epirubicin between the two cell stable cell lines.
Also, in cells derived from SK-MES-1, DHX36 knockdown
showed a higher proliferation level in response to 12nM
paclitaxel compared to the SCR control (p<0.01), which was not
observed in the treatments with 6 nM paclitaxel. Likewise, DHX36
knockdown in the SK-MES-1 cells led to a higher remaining
proliferation level compared to the SCR control after treatment
with 5 µM etoposide (p<0.01). In the stable A549 cells (Figure
5H), a significant difference of the proliferation levels between the
DHX36 group and its SCR control could only be observed







FIGURE 2 | Validation of the stable cell lines with DHX36 shRNAs. Gene expression in A549 (A) and SK-MES-1 (B). Flow cytometry analysis of DHX36 protein
expression in A549 containing SCR (C), A549 containing DHX36 shRNA1 (D), A549 containing DHX36 shRNA2 (E), SK-MES-1 containing SCR (F), SK-MES-1
containing DHX36 shRNA1 (G), SK-MES-1 containing DHX36 shRNA1 (H). Western blots of DHX36 protein in A549 (I) and SK-MES-1 (J).April 2021 | Volume 11 | Article 655757
Cui et al. DHX36 in Lung CancerProteomic Analysis Indicated the Change
of Signalling Pathways After the
Knockdown of DHX36
We conducted the Kinex antibody array to understand whether the
knockdown of DHX36 could alter the signalling profile of the stable
A549 cell lines. The upregulated proteins are outlined in Figure 6A,
while the downregulated proteins are outlined in Figure 6B. The
heatmap of the antibody arrays is shown in Figure 6C. To depict theFrontiers in Oncology | www.frontiersin.org 8linkages of the altered proteins and the most significant biological
functions in a signalling complex network, we conducted protein
enrichment plotting using a Bioconductor package of genome-wide
annotation for human (org.Hs.eg.db). As shown in Figure 6D, the
most significant biological functions that DHX36 regulated were
activation of protein activity, protein autophosphorylation, Fc
receptor signalling pathway, response to peptide hormone and





FIGURE 3 | The effect of the knockdown of the DHX36 gene on cell migration, cell cycle and apoptosis. The migration was monitored by the ECIS system in the
stable cell lines derived from A549 (A) and SK-MES-1 (B). (C) Cell cycle analysis of A549 SCR. (D) Cell cycle analysis of A549 DHX36 KD. (E) Cell cycle analysis of
SK-MES-1 SCR. (F) Cell cycle analysis of SK-MES-1 KD. (G) Apoptosis of the A549 SCR treated with PBS. (H) Apoptosis of the A549 DHX36 KD treated with
cisplatin (10 µM, 24 h). (I) Apoptosis of the SK-MES-1 DHX36 KD treated with PBS. (J) Apoptosis of the SK-MES-1 DHX36 KD treated with cisplatin.April 2021 | Volume 11 | Article 655757
Cui et al. DHX36 in Lung CancerDifferential Expression Analysis Unveiled
the Role of DHX36 in Gene Regulation in
Lung Cancer
We performed bioinformatic analysis of the TCGA RNA-Seq
datasets of lung cancer in order to identify the causal regulation
pathway signature. The heatmap plotting of the DHX36-
associated differential genes in LUAD and LUSC showed that
DHX36 had different transcript profiles while sharing certain
levels of similarity (Figure 7A). As a result of the gene setFrontiers in Oncology | www.frontiersin.org 9enrichment analysis, DHX36 was associated with mRNA
surveillance, RNA degradation, DNA replication and Myc
targets in both subtypes (Figures 7B, C). In LUAD, DHX36 was
also associated with protein secretion, cell cycle G2/M transition,
mitotic spindle organization, and nucleotide excision repair. In
LUSC, DHX36 was also associated with interferon a response,
TGFb signalling, negative regulation of interleukin 1b production,
chromosome separation, mRNA 3’-end processing, regulation of





FIGURE 4 | Growth and viability analysis of the 3D tumour spheroids. (A) Representative images of the lung cancer cell spheroids. The spheroids were stained with
propidium iodide (PI) to indicate cell death. (B) The value of GFP and PI in the stable A549 cell lines. (C) The ratio of GFP/PI in the stable A549 cell lines indicating
the viability level. (D) The value of GFP and PI in the stable SK-MES-1 cell lines. (E) The ratio of GFP/PI in the stable SK-MES-1 cell lines. (F) Comparison of the sizes
(indicated by the maximum area) of the spheroids.April 2021 | Volume 11 | Article 655757
Cui et al. DHX36 in Lung CancerDISCUSSION
There is no previous report of the clinical significance of DHX36
in lung cancer. We show that the gene expression level of DHX36
is negatively associated with patients with NSCLC. The meta-
analysis of all the publicly available datasets from previous
studies indicates the negative association exists in LUAD
instead of in LUSC. However, our differential gene expression
analysis indicates that in both LUSC and LUAD subtypes, theFrontiers in Oncology | www.frontiersin.org 10levels of DHX36 gene expression in lung cancer are higher than
in normal tissues. Therefore DHX36 indeed plays a role in
indicating malignancy and subtype-dependent patient survival.
An analysis of the clinical significance in pan cancers using a web
server GEPIA (http://gepia2.cancer-pku.cn) further confirms
that DHX36 gene expression is increased in lung cancer but is
varied in other cancers (Supplementary Figure 1A). NSCLC is
the cancer type with the second-highest frequency of altered





FIGURE 5 | Single-cell colony formation and cellular response to cytotoxic drugs. (A) In situ heatmap of the single-cell colony formation from the A549 SCR cell line
in a 96-well plate following cultivation for 3 weeks. The values are fluorescent intensity (FI) indicated by the Alamar Blue proliferation assay. (B) In situ heatmap of the
single-cell colony formation from the A549 KD cell line. (C) In situ heatmap of the single-cell colony formation from the SK-MES-1 SCR cell line. (D) In situ heatmap
of the single-cell colony formation from the SK-MES-1 KD cell line. (E) Quantification of the colony numbers following single-cell culture. (F) Analysis of the FI values
of the colonies indicated by Alamar Blue. (G) Cytotoxic response of the stable A549 cell lines to chemotherapeutic drugs indicated by Alamar Blue. The normalised
proliferation index is calculated by the division of the FI value of each group with the PBS group. (H) Cytotoxic response of the stable SK-MES-1 cell lines to
chemotherapeutic drugs. *p < 0.05, **p < 0.01.April 2021 | Volume 11 | Article 655757
Cui et al. DHX36 in Lung CancerGenomics (https://www.cbioportal.org) (Supplementary
Figure 1B).
Although the TCGA dataset shows higher expression of
DHX36 gene in tumour tissue, which is in line with the altered
protein levels in a CPTAC dataset, there are also other studies
showing that the transcript level of DHX36 is lower in the tumour
samples (Supplementary Figure 2). These discrepancies may
occur due to the sampling method, low numbers of normal
controls, tumour tissue heterogeneity or normalisation
algorithms. Future studies, with large-scale high-quality samplesFrontiers in Oncology | www.frontiersin.org 11and techniques with high sensitivity and accuracy, may enable us
to make a robust conclusion.
Using the validated shRNA we can establish stable lung
cancer cell lines with DHX36 knockdown. We demonstrate
that the knockdown of DHX36 enhances the migration
capacity of lung cancer cells. Whilst there is no previous report
of DHX36 function in lung cancer, there is indirect evidence
with DHX9, a DHX36 paralog among the DEAH-box helicases.
DHX9 and DHX36 are the only two helicase enzymes
that have been reported to unwind both DNA and RNAA
B
DC
FIGURE 6 | Kinex antibody microarray analysis of signal transduction after DHX36 was knocked down in A549 cells. (A) Upregulated proteins with z ratio>1
(B) Downregulated proteins with z ratio<-1 (C) Heatmaps of the Kinex antibody arrays. (D) Key signalling pathways identified using the clusterProfiler Bioconductor
package in R language.April 2021 | Volume 11 | Article 655757
Cui et al. DHX36 in Lung CancerG-quadruplexes (41, 79). These two helicases share the domains
of the DEAH motif, a domain of the unknown function (DUF),
helicase-associated domain 2 (HA2) and helicase C-terminal
domain (49). It is reported that the knockdown of DHX9 can
promote the migration of A549 cells, suggesting they may have a
similarity in the role of mediating the migration of cancer cells
through a shared functional domain (80). For potential
mechanisms, our protein array data show that after the
knockdown of DHX36, there is a significant increase of
migration driver Protein Kinase C a (PKCA) in the stable cellFrontiers in Oncology | www.frontiersin.org 12line. PKCA is considered to repress the transcription of p120-
catenin, leading to the destabilisation of E-cadherin and the
dissociation of adhesion junctions, therefore promoting cell
migration (81).
We show that there is an accumulation of S-phase cell
population after DHX36 knockdown, suggesting that DHX36
plays a role in modulating DNA replication and cell cycle
progression. There is experimental evidence that DHX36
increases the translational efficiency of its targets through
harbouring and unwinding the nucleic acid G4 structures (82).A
B
C
FIGURE 7 | Heatmap plotting and causal pathway analysis of the differential transcript profiles affected by DHX36 in LUAD and LUSC. The bioinformatic analysis
was conducted using the Pathview Bioconductor package in R. The lung cancer RNA-Seq datasets were obtained from TCGA. (A) Heatmap visualisation of the
differential transcripts affected by DHX36. (B) Causal gene set enrichment analysis in LUAD. (C) Causal gene set enrichment analysis in LUSC. The enrichment
scores were obtained using multiplex pathway databases including Gene ontology terms (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and the
Molecular Signatures Database (MSigDB) HALLMARK sets. nlgpval is the abbreviation of the negative log of p value.April 2021 | Volume 11 | Article 655757
Cui et al. DHX36 in Lung CancerThe cell cycle is regulated by various cyclin-dependent kinases
(CDKs), a group of serine/threonine-specific protein kinases with
approximately 20members (83). The formation of the CDK-cyclin
complex enhances the accumulation of the prospective phase in a
cell cycle. Our Kinex antibody array analysis indicates that the
phosphorylation levels of CDK6 and CDK9 are increased in
response to the DHX36 knockdown. CDK6 is known to form a
complexwith cyclinD and drive the cell-cycle progression from the
G0/G1 phase into the S phase (84). CDK9 plays a regulatory role in
the transcription of cyclins such as upregulating cyclin D but
downregulating cyclin E, thus is vital in the completion of DNA
synthesis in response to replication stress (85).
Cancer cells can be less quiescentwhen there is an accumulation
of S-phase population, hence may be more susceptible to
chemotherapeutic drugs. We show, however, that lung cancer
cells exhibit less or similar cytotoxicity in response to therapeutic
drugs including cisplatin, epirubicin, paclitaxel and etoposide. This
implies that the drug response in lung cancer cells can be varied and
may depend on multiple factors such as cell division, metabolism,
uptake and targeting mechanisms (86).
High throughput proteomics may better identify the altered
signalling pathways in cancer cells after gene knockdown. Our
high throughput antibody analysis indicates that, after the
knockdown of the DHX36 gene in stable cell lines, key cellular
signalling transduction occurs from protein kinase activation,
protein phosphorylation, Fc receptor signalling, response to
peptide hormone and stress-activated protein kinases. This
demonstrates that DHX36 is indeed a multifunctional protein
and its role in the stress process in tumour cells.
We have attempted to explore the causal regulator of the
DHX36 function by taking advantage of the TCGA datasets.
There is a certain similarity of the differential gene expression
profile associated with DHX36 levels between two NSCLC
subtypes. For causal pathways highlighted, mRNA surveillance
functions through quality control to induce the degradation of
aberrant mRNA thus preventing its translation to cytotoxic
proteins. Although the role of mRNA surveillance in cancer
can be complicated, there may be potential to target this pathway
and allow the formation of truncated proteins with loss of
function. DHX36 has also been reported to resolve the G4s
which are located in either the 5’-UTR or the 3-UTR of mRNAs
and modulate their degradation (87). In addition, the relatively
stable folded G4s in the single-stranded DNA can be disrupted
by DHX36 in an ATP-dependent manner, which therefore
regulates the position of the DNA forks in replication, and
may shift genetic instability caused by aberrant DNA G4s. The
complex of DHX36-specific motif (DSM) and the G4-enriched c-
Myc promoter sequence has been unveiled by crystal structure
modelling (46). It is therefore understandable that DHX36 plays
a role in regulating the pathway of the Myc targets. It is known
that as a proto-oncogene, Myc drives downstream transcription
amplification thus leading to augmented tumour growth. In
contrast, our data suggest that DHX36 is a tumour suppressor
based on a variety of cellular assays. We, therefore, speculate that
DHX36 is multifunctional but may not be predominantly
through the Myc target activity.Frontiers in Oncology | www.frontiersin.org 13Our data indicate that DHX36 is a novel independent
prognosis indicator in NSCLC with subtype dependence using
both publicly available large-scale datasets and our in-house
cohort. The stable lentiviral knockdown of the DHX36 allows
us to determine the role of DHX36 as a tumour suppressor
through a variety of cellular and molecular assays including
migration, ECIS, 3D tumour model and single-cell colony
formation. Interestingly, we also identify the effect of DHX36
on tumour cell susceptibility to chemotherapeutic drugs, which
imply its therapeutic potential. Given the nature that DHX36 is a
multifunctional G4-structure resolvase, that may influence the
multiple steps of RNA metabolism, we explore transcriptomics
and proteomics in systematic ways to outline the critical
regulation, alteration and lead signalling pathways in which
DHX36 may be involved in lung cancer. Future studies should
be encouraged to pin-point the actual cellular and molecular
mechanisms of DHX36 function in lung cancer by either
activation or overexpression of DHX36, which could be
proceeded by either CRISPR-based genomic editing or small
molecules predicted by chemical docking simulation. It is
possible to better verify the functions of DHX36 by the
combination of two-way regulation of this molecule or even
ideally in an inducible manner. The possible discovery of DHX36
targeting may be translated to the treatment of lung cancer
starting from an appropriate in vivo pre-clinical model.
CONCLUSION
In this study, we show that DHX36 can be an independent
prognosis indicator in NSCLC with subtype dependence. The
stable knockdown of this helicase leads to promoted tumour
growth, under 3D cultivation conditions and augmented cell
colony formation, following single-cell cultivation. The DHX36
knockdown accelerates migration and aggregation of the S-phase
subpopulation in lung cancer cells. Furthermore, the reduction of
DHX36 level de-sensitises the proliferation response of lung
cancer cells to chemotherapeutic drugs such as paclitaxel, with
cell dependence. DHX36 functions through regulating multiple
signalling pathways including activation of protein activity,
protein autophosphorylation, Fc-receptor signalling pathway,
response to peptide hormone and stress-activated protein
kinase signalling cascade in lung cancer cells. A causal
transcriptomic analysis suggests that DHX36 is significantly
associated with mRNA surveillance, RNA degradation, DNA
replication and Myc targets. Therefore, we unveil that DHX36
presents clinical significance and plays a role in tumour
suppression in lung cancer, and propose a potentially
new concept for an anti-cancer therapy based on helicase-
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Supplementary Figure 1 | Pan-cancer analysis of DHX36 gene expression.
(A) Analysis using the GEPIA bioinformatic server. (B) Analysis using the cBioPortal
for Cancer Genomics.
Supplementary Figure 2 | Additional analysis of the gene and protein expression
levels of DHX36 in lung cancer. (A) The breakdown meta-analysis of the differential
expression of DHX36 gene in lung cancer tissues using the Lung Cancer Explorer
(http://lce.biohpc.swmed.edu). (B) Paired comparison of DHX36 gene expression
in a gene microarray study (GSE18842). (C) The analysis of the DHX36 protein
levels in lung cancer using the Clinical Proteomic Tumor Analysis Consortium
(CPTAC).
Supplementary Figure 3 | Initial cytotoxicity assay of the cell lines in response to
cisplatin for the determination of the optimum dose for apoptosis detection. (A) Raw
fluorescence reads of viable cells indicated by the Alamar Blue assay. (B) Normalised
cell viability ratio.REFERENCES
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